However, inhibition of the myostatin pathways gives only little or no effect in the severe SMA transgenic mice.31, 32, 33 In agreement with these observations, we showed in this study that systemic administration of AAV‐MPRO in neonatal severe SMA mice had only a very modest effect on survival (Figure1). This evidence concerns the gene MSTN and proximal spinal muscular atrophy.